Panitumumab for locally advanced head and neck squamous-cell carcinoma

Affiliations

¹ Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: ishiki-tky@umin.ac.jp.
² Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
³ The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Comment

Hiroto Ishiki et al. Lancet Oncol. 2015 Apr.

. 2015 Apr;16(4):e156.

doi: 10.1016/S1470-2045(15)70101-4.

¹ Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: ishiki-tky@umin.ac.jp.
² Department of Palliative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
³ The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

No abstract available

Comment on

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Mesía R, et al. Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15. Lancet Oncol. 2015. PMID: 25596660 Clinical Trial.